FCAG
LXRX icon

First Capital Advisors Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

First Capital Advisors Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,254
Closed -$11K – 515
2018
Q1 		$11K Buy
+1,254
New +$11.6K 0.01% 528

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
SGA
Sector Gamma AS Oslo, Norway $461M AUM 33.26% 1-Year Est. Return

First Capital Advisors Group's LXRX Position: Q2 2018 in Review

First Capital Advisors Group sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2018, closing a stake of 1,254 shares — an estimated $11K sold.

First Capital Advisors Group first reported a position in LXRX in Q1 2018 and held it in 1 quarter. The position peaked at $11K in Q1 2018. 121 funds tracked by Wall St. Rank hold LXRX as of Q2 2018.

  • First Capital Advisors Group reported no remaining Lexicon Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • First Capital Advisors Group sold 1,254 Lexicon Pharmaceuticals shares in Q2 2018, an estimated $11K.
  • First Capital Advisors Group first reported a position in Lexicon Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • First Capital Advisors Group's Lexicon Pharmaceuticals position peaked at $11K in Q1 2018.
  • 121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2018.

Based on First Capital Advisors Group's 13F filing for Q2 2018, filed 30 Jul 2018.